Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioRexis Pharmaceutical Corp.

Division of Pfizer Inc.
www.biorexis.com

Latest From BioRexis Pharmaceutical Corp.

Merck's Head-long Leap into Follow-On Biologics

Merck outlined ambitious and capital-intensive plans for a biosimilars business at its annual investor day in early December. The company aims to leverage its 2006 acquisition of GlycoFi to launch six or more follow-on biologics between 2012 and 2017. The news shifts the Big Pharma in an entirely new direction, one that pharmaceutical companies--with the exception of Novartis AG's Sandoz division--have largely stayed away from.
BioPharmaceutical Business Strategies

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.
BioPharmaceutical Strategy

BioRexis Pharmaceutical Corp.

BioRexis Pharmaceutical hopes to solve the problems with protein drugs by exploiting a previously overlooked human protein as a novel protein fusion scaffold. If the company's technology works, BioRexis could build a diverse product pipeline fast, with much lower manufacturing costs and without any outside IP encumbrance.
BioPharmaceutical

Start-Up Previews (6/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Filling in the Gaps in AAA Repair, features CardioMEMS Inc., EVA Corp. and Medical Metrx Solutions Inc.. Plus these Start-Ups across Health Care: BioRexis Pharmaceutical Corp., Calypso Medical Technologies Inc., Chaperone Technologies Inc., QRxPharma Pty. Ltd. and Sequential Inc.
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • David R King, CEO
    Michael Celano, VP, Fin. & CFO
  • Contact Info
  • BioRexis Pharmaceutical Corp.
    Phone: (610) 313-4000
    3400 Horizon Dr.
    King of Prussia, PA 19406
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register